Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Funny, Guess they allow dogs in the office?

<< Previous

Bullboard Posts

Next >>

Comment by jfm1330on Aug 11, 2021 3:29pm

84 Views

Post# 33686157

RE:RE:RE:Funny, Guess they allow dogs in the office?

I forgot that. He alluded twice to the possibility of spectacular results in oncology. Also, Dubuc said that they could raise money if they would expand the Phase Ib after discussions with the FDA. It's too early for them to say anything in oncology, but there are a lot of positive signs from them.